Rezolute, Inc. has announced a significant milestone in its clinical development program. The company has completed enrollment in its Phase 3 upLIFT study, which investigates the efficacy of its investigational drug, ersodetug, for treating tumor hyperinsulinism. This development is crucial as it brings the company closer to potentially providing a new treatment option for patients suffering from this rare condition.
Rezolute, Inc., based in Redwood City, California, operates within the pharmaceutical preparations sector, specifically focusing on ultra-rare diseases. The company is publicly traded on the Nasdaq under the ticker symbol RZLT. Rezolute has been actively involved in clinical trials for its lead product, ersodetug, which aims to address refractory hypoglycemia caused by hyperinsulinism.
According to the recent SEC filing, dated October 14, 2026, the company stated, "On October 14, 2026, Rezolute, Inc. issued a press release to announce an update on patient enrollment in the Company’s upLIFT study." This press release highlighted that the study is now fully enrolled and that topline results are anticipated by mid-December 2026.
The completion of enrollment in the upLIFT study is expected to impact various stakeholders, including patients with tumor hyperinsulinism, healthcare providers, and investors. Patients will benefit from the potential availability of a new treatment option, while healthcare providers may gain a new tool to manage this challenging condition. Investors will be keenly watching the upcoming topline results, which could influence the company's stock performance and future funding opportunities.
Looking ahead, the company plans to continue its expanded access program for ersodetug, allowing compassionate use for individuals suffering from serious and refractory hypoglycemia due to tumor hyperinsulinism. This program aims to provide patients with access to the treatment while the company awaits regulatory approval.